A few thoughts on Patrys' current work and DX1's future path

Just got some ideas from the below information found on the Internet:

"But over the next few months Dr Lebowitz and his colleagues made several trips to China to carry out due diligence and became confident that Legend’s Car-T, codenamed LCAR-B38M, was a “spectacular asset”... In December, the pair struck a deal. J&J paid Legend $350m to enter an agreement whereby the companies will share the costs of developing the Car-T and split the profits if it is approved by regulators in the US and China.

Dr Lebovitz thinks LCAR-B38M could be superior to a rival Car-T being developed in a partnership by Bluebird Bio and Celgene, two US-based biotech companies, which is generally seen as the most advanced product in the race to tackle multiple myeloma...One reason could be that Legend’s CAR-T binds to two spots on the cancer-causing protein, he says. “If you’re going to grab a basketball, then it’s easier to grab with two hands than one.”
- Healthcare: Cancer breakthrough leads China’s biotech boom
https://www.ft.com/content/30b5a944-3b57-11e8-b9f9-de94fa33a81e

It seems J&J took less than half year to complete the whole process of negotiation, due diligence, and striking a deal. As we all know, a blockbuster IP is very hard to find and get. This deal demonstrates J&J is an expert judge of IP targets and an efficient doer. Now Patrys is in the process of building its leading position at the forefront of the DDR therapeutics, and has already established a very strong IP position ...

As mentioned in Patrys' AACR poster, currently work is ongoing to establish DX1 intracellular targets. It does make sense - the more targets, the more application scenarios, and thus the higher value of DX1.


"It’s a fairy tale for IFM to be swept up in a blockbuster deal (2.3B) just a year after a series A and with such early-stage candidates. Of course, BMS is no stranger to biotech buyouts. Gaining rights to early-stage assets gives the licensee more flexibility to shape its development. Furthermore, early-stage assets often comprise of "platforms" which could deliver multiple new drugs. Increased competition for early stage assets appears to be driving total deal values higher in this sector."
- Excerpt from Internet

In March 2018 Appendix 4C, it says Further preclinical work to optimise dosing and scheduling of PAT‐DX1 in a range of cancers will continue in 2018. So, it is likely that DX1 could be further developed to comprise of "platforms" which could apply to more indications and accordingly deliver multiple new drugs and thus unlock its great potential. As the CEO said last September, the management have a very clear vision of where this technology goes.

Keep faith and keep patience. The future of DX1 is bright imo.

DYOR